Advarra Acquires IntegReview IRB
Advarra is pleased to announce the acquisition of IntegReview IRB. The addition of IntegReview enables Advarra to continue its expansion of comprehensive review solutions capabilities in North America.
“IntegReview and Advarra share a mission-driven passion for protecting clinical trial participants,” said Gadi Saarony, CEO of Advarra. “Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service. We are excited to welcome more talent to enhance our combined capabilities and geographic footprint.”
The Austin, Tex. headquarters for IntegReview will become the first Advarra office in the southern US. The acquisition also increases depth of expertise in many key areas, most notably in early phase research.
“We are excited to be a part of the Advarra family” said Lynn Meyer, founder and Managing Partner of IntegReview. “We were attracted to Advarra’s extensive regulatory depth and their model of integrated IRB operations and focus on building client relationships and deep collaboration with the site community.”
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
